<?xml version="1.0" encoding="UTF-8"?><TED_EXPORT xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="ted/R2.0.8.S03/publication" xmlns:n2016="ted/2016/nuts" xsi:schemaLocation="ted/R2.0.8.S03/publication TED_EXPORT.xsd" DOC_ID="027354-2018" EDITION="2018013"><TECHNICAL_SECTION><RECEPTION_ID>18-026694-001</RECEPTION_ID><DELETION_DATE>20180428</DELETION_DATE><FORM_LG_LIST>DE </FORM_LG_LIST><COMMENTS>From Convertor</COMMENTS></TECHNICAL_SECTION><LINKS_SECTION><XML_SCHEMA_DEFINITION_LINK xlink:type="simple" xlink:href="http://ted.europa.eu" xlink:title="TED WEBSITE"/><OFFICIAL_FORMS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/><FORMS_LABELS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/><ORIGINAL_CPV_LINK xlink:type="simple " xlink:href="http://ted.europa.eu"/><ORIGINAL_NUTS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/></LINKS_SECTION><CODED_DATA_SECTION><REF_OJS><COLL_OJ>S</COLL_OJ><NO_OJ>13</NO_OJ><DATE_PUB>20180119</DATE_PUB></REF_OJS><NOTICE_DATA><NO_DOC_OJS>2018/S 013-027354</NO_DOC_OJS><URI_LIST><URI_DOC LG="DE">http://ted.europa.eu/udl?uri=TED:NOTICE:027354-2018:TEXT:DE:HTML</URI_DOC></URI_LIST><LG_ORIG>DE</LG_ORIG><ISO_COUNTRY VALUE="DE"/><IA_URL_GENERAL>http://aok-niedersachsen.de</IA_URL_GENERAL><ORIGINAL_CPV CODE="33652100">Antineoplastic agents</ORIGINAL_CPV><VALUES_LIST/></NOTICE_DATA><CODIF_DATA><DS_DATE_DISPATCH>20180118</DS_DATE_DISPATCH><AA_AUTHORITY_TYPE CODE="6">Body governed by public law</AA_AUTHORITY_TYPE><TD_DOCUMENT_TYPE CODE="7">Contract award notice</TD_DOCUMENT_TYPE><NC_CONTRACT_NATURE CODE="2">Supplies</NC_CONTRACT_NATURE><PR_PROC CODE="V">Contract award without prior publication</PR_PROC><RP_REGULATION CODE="5">European Union, with participation by GPA countries</RP_REGULATION><TY_TYPE_BID CODE="9">Not applicable</TY_TYPE_BID><AC_AWARD_CRIT CODE="Z">Not specified</AC_AWARD_CRIT><MA_MAIN_ACTIVITIES CODE="8">Other</MA_MAIN_ACTIVITIES><HEADING>01203</HEADING><DIRECTIVE VALUE="2004/18/EC"/></CODIF_DATA></CODED_DATA_SECTION><TRANSLATION_SECTION><ML_TITLES><ML_TI_DOC LG="BG"><TI_CY>Гepмaния</TI_CY><TI_TOWN>Хановер</TI_TOWN><TI_TEXT>Антинеопластични средства</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="CS"><TI_CY>Německo</TI_CY><TI_TOWN>Hanover</TI_TOWN><TI_TEXT>Antineoplastika</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="DA"><TI_CY>Tyskland</TI_CY><TI_TOWN>Hannover</TI_TOWN><TI_TEXT>Cytostatika</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="DE"><TI_CY>Deutschland</TI_CY><TI_TOWN>Hannover</TI_TOWN><TI_TEXT>Antineoplastische Mittel</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="EL"><TI_CY>Γερμανία</TI_CY><TI_TOWN>Ανόβερο</TI_TOWN><TI_TEXT>Αντινεοπλασματικά φάρμακα</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="EN"><TI_CY>Germany</TI_CY><TI_TOWN>Hanover</TI_TOWN><TI_TEXT>Antineoplastic agents</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="ES"><TI_CY>Alemania</TI_CY><TI_TOWN>Hannover</TI_TOWN><TI_TEXT>Agentes antineoplásicos</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="ET"><TI_CY>Saksamaa</TI_CY><TI_TOWN>Hannover</TI_TOWN><TI_TEXT>Antineoplastilised ained</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="FI"><TI_CY>Saksa</TI_CY><TI_TOWN>Hannover</TI_TOWN><TI_TEXT>Solunsalpaajat ja sytostaatit</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="FR"><TI_CY>Allemagne</TI_CY><TI_TOWN>Hanovre</TI_TOWN><TI_TEXT>Antinéoplasiques</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="GA"><TI_CY>Ghearmáin, an</TI_CY><TI_TOWN>Hanover</TI_TOWN><TI_TEXT>Antineoplastic agents</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="HR"><TI_CY>Njemačka</TI_CY><TI_TOWN>Hannover</TI_TOWN><TI_TEXT>Antineoplastični lijekovi</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="HU"><TI_CY>Németország</TI_CY><TI_TOWN>Hannover</TI_TOWN><TI_TEXT>Daganatellenes szerek</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="IT"><TI_CY>Germania</TI_CY><TI_TOWN>Hannover</TI_TOWN><TI_TEXT>Agenti antineoplastici</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="LT"><TI_CY>Vokietija, VFR</TI_CY><TI_TOWN>Hanoveris</TI_TOWN><TI_TEXT>Antinavikiniai vaistai</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="LV"><TI_CY>Vācija</TI_CY><TI_TOWN>Hanovera</TI_TOWN><TI_TEXT>Antineoplastiskie līdzekļi</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="MT"><TI_CY>il-Ġermanja</TI_CY><TI_TOWN>Hanover</TI_TOWN><TI_TEXT>Aġenti ta' l-antineoplastika</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="NL"><TI_CY>Duitsland</TI_CY><TI_TOWN>Hannover</TI_TOWN><TI_TEXT>Antineoplastische middelen</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="PL"><TI_CY>Niemcy</TI_CY><TI_TOWN>Hanower</TI_TOWN><TI_TEXT>Środki przeciwnowotworowe</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="PT"><TI_CY>Alemanha</TI_CY><TI_TOWN>Hanôver</TI_TOWN><TI_TEXT>Antineoplásicos</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="RO"><TI_CY>Germania</TI_CY><TI_TOWN>Hanovra</TI_TOWN><TI_TEXT>Antineoplazice</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SK"><TI_CY>Nemecko</TI_CY><TI_TOWN>Hannover</TI_TOWN><TI_TEXT>Antineoplastické činidlá</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SL"><TI_CY>Nemčija</TI_CY><TI_TOWN>Hannover</TI_TOWN><TI_TEXT>Zdravila z delovanjem na novotvorbe</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SV"><TI_CY>Tyskland</TI_CY><TI_TOWN>Hannover</TI_TOWN><TI_TEXT>Cytostatika/cytotoxiska medel</TI_TEXT></ML_TI_DOC></ML_TITLES><ML_AA_NAMES><AA_NAME LG="DE">AOK – Die Gesundheitskasse für Niedersachsen</AA_NAME></ML_AA_NAMES></TRANSLATION_SECTION><FORM_SECTION><CONTRACT_AWARD CATEGORY="ORIGINAL" FORM="3" LG="DE" VERSION="R2.0.8.S03.E01"><FD_CONTRACT_AWARD CTYPE="SUPPLIES"><CONTRACTING_AUTHORITY_INFORMATION_CONTRACT_AWARD><NAME_ADDRESSES_CONTACT_CONTRACT_AWARD><CA_CE_CONCESSIONAIRE_PROFILE><ORGANISATION><OFFICIALNAME>AOK – Die Gesundheitskasse für Niedersachsen</OFFICIALNAME></ORGANISATION><ADDRESS>Hildesheimer Str. 273</ADDRESS><TOWN>Hannover</TOWN><POSTAL_CODE>30519</POSTAL_CODE><COUNTRY VALUE="DE"/><ATTENTION>Andreas Hoffmann</ATTENTION><PHONE>+49 5118701-15210</PHONE><E_MAILS><E_MAIL>Andreas.Hoffmann@nds.aok.de</E_MAIL></E_MAILS><FAX>+49 51128533-15210</FAX></CA_CE_CONCESSIONAIRE_PROFILE><INTERNET_ADDRESSES_CONTRACT_AWARD><URL_GENERAL>http://aok-niedersachsen.de</URL_GENERAL></INTERNET_ADDRESSES_CONTRACT_AWARD></NAME_ADDRESSES_CONTACT_CONTRACT_AWARD><TYPE_AND_ACTIVITIES_AND_PURCHASING_ON_BEHALF><TYPE_AND_ACTIVITIES><TYPE_OF_CONTRACTING_AUTHORITY VALUE="BODY_PUBLIC"/><TYPE_OF_ACTIVITY_OTHER VALUE="OTHER">Gesetzliche Krankenversicherung</TYPE_OF_ACTIVITY_OTHER></TYPE_AND_ACTIVITIES><PURCHASING_ON_BEHALF><PURCHASING_ON_BEHALF_NO/></PURCHASING_ON_BEHALF></TYPE_AND_ACTIVITIES_AND_PURCHASING_ON_BEHALF></CONTRACTING_AUTHORITY_INFORMATION_CONTRACT_AWARD><OBJECT_CONTRACT_INFORMATION_CONTRACT_AWARD_NOTICE><DESCRIPTION_AWARD_NOTICE_INFORMATION><TITLE_CONTRACT><P>Rabattvereinbarung gem. § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Midostaurin</P></TITLE_CONTRACT><TYPE_CONTRACT_LOCATION_W_PUB><TYPE_CONTRACT VALUE="SUPPLIES"/><TYPE_SUPPLIES_CONTRACT VALUE="PURCHASE"/></TYPE_CONTRACT_LOCATION_W_PUB><NOTICE_INVOLVES_DESC><CONCLUSION_FRAMEWORK_AGREEMENT/></NOTICE_INVOLVES_DESC><SHORT_CONTRACT_DESCRIPTION><P>Vereinbarung von Rabatten gem. § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Midostaurin</P></SHORT_CONTRACT_DESCRIPTION><CPV><CPV_MAIN><CPV_CODE CODE="33652100"/></CPV_MAIN></CPV><CONTRACT_COVERED_GPA VALUE="YES"/></DESCRIPTION_AWARD_NOTICE_INFORMATION></OBJECT_CONTRACT_INFORMATION_CONTRACT_AWARD_NOTICE><PROCEDURE_DEFINITION_CONTRACT_AWARD_NOTICE><TYPE_OF_PROCEDURE_DEF><F03_AWARD_WITHOUT_PRIOR_PUBLICATION><ANNEX_D><NO_MANUFACTURED_BY_DIRECTIVE/><JUSTIFICATION_CHOICE_NEGOCIATED_PROCEDURE><REASONS_PROVIDED_PARTICULAR_TENDERER><REASONS_PROVIDED_PARTICULAR_TENDERER_EXCLUSIVE_RIGHTS/></REASONS_PROVIDED_PARTICULAR_TENDERER><NO_EXTREME_URGENCY_EVENTS_UNFORESEEABLE/><NO_ADDITIONAL_WORKS/><NO_SUPPLIES_QUOTED_PURCHASED_COMMODITY_MARKET/></JUSTIFICATION_CHOICE_NEGOCIATED_PROCEDURE><NO_ONLY_IRREGULAR_INACCEPTABLE_TENDERERS/></ANNEX_D></F03_AWARD_WITHOUT_PRIOR_PUBLICATION></TYPE_OF_PROCEDURE_DEF><ADMINISTRATIVE_INFORMATION_CONTRACT_AWARD><PREVIOUS_PUBLICATION_INFORMATION_NOTICE_F3><NO_PREVIOUS_PUBLICATION_EXISTS_F3/></PREVIOUS_PUBLICATION_INFORMATION_NOTICE_F3></ADMINISTRATIVE_INFORMATION_CONTRACT_AWARD></PROCEDURE_DEFINITION_CONTRACT_AWARD_NOTICE><AWARD_OF_CONTRACT><CONTRACT_TITLE><P>Midostaurin</P></CONTRACT_TITLE><ECONOMIC_OPERATOR_NAME_ADDRESS><CONTACT_DATA_WITHOUT_RESPONSIBLE_NAME><ORGANISATION><OFFICIALNAME>Novartis Pharma GmbH</OFFICIALNAME></ORGANISATION><ADDRESS>Roonstraße 25</ADDRESS><TOWN>Nürnberg</TOWN><POSTAL_CODE>90429</POSTAL_CODE><COUNTRY VALUE="DE"/></CONTACT_DATA_WITHOUT_RESPONSIBLE_NAME></ECONOMIC_OPERATOR_NAME_ADDRESS><MORE_INFORMATION_TO_SUB_CONTRACTED><NO_CONTRACT_LIKELY_SUB_CONTRACTED/></MORE_INFORMATION_TO_SUB_CONTRACTED></AWARD_OF_CONTRACT><COMPLEMENTARY_INFORMATION_CONTRACT_AWARD><RELATES_TO_EU_PROJECT_NO/><PROCEDURES_FOR_APPEAL><APPEAL_PROCEDURE_BODY_RESPONSIBLE><CONTACT_DATA_WITHOUT_RESPONSIBLE_NAME><ORGANISATION><OFFICIALNAME>Vergabekammer des Bundes</OFFICIALNAME></ORGANISATION><ADDRESS>Villemombler Straße 76</ADDRESS><TOWN>Bonn</TOWN><POSTAL_CODE>53123</POSTAL_CODE><COUNTRY VALUE="DE"/></CONTACT_DATA_WITHOUT_RESPONSIBLE_NAME></APPEAL_PROCEDURE_BODY_RESPONSIBLE><LODGING_OF_APPEALS><LODGING_OF_APPEALS_PRECISION><P>Für die Einleitung eines Nachprüfungsverfahrens gilt u. a. die folgende Bestimmung des Gesetzes gegen Wettbewerbsbeschränkungen (GWB): „§ 107 Einleitung, Antrag. </P><P>1) Die Vergabekammer leitet ein Nachprüfungsverfahren nur auf Antrag ein. </P><P>2) Antragsbefugt ist jedes Unternehmen, das ein Interesse am Auftrag hat und eine Verletzung in seinen Rechten nach § 97 Abs. 7 durch Nichtbeachtung von Vergabevorschriften geltend macht. Dabei ist darzulegen, dass dem Unternehmen durch die behauptete Verletzung der Vergabevorschriften ein Schaden entstanden ist oder zu entstehen droht. </P><P>3) Der Antrag ist unzulässig, soweit: </P><P>a. der Antragsteller den gerügten Verstoß gegen Vergabevorschriften im Vergabeverfahren erkannt und gegenüber dem Auftraggeber nicht unverzüglich gerügt hat, </P><P>b. Verstöße gegen Vergabevorschriften, die aufgrund der Bekanntmachung erkennbar sind, nicht spätestens bis Ablauf der in der Bekanntmachung benannten Frist zur Angebotsabgabe oder zur Bewerbung gegenüber dem Auftraggeber gerügt werden, </P><P>c. Verstöße gegen Vergabevorschriften, die erst in den Vergabeunterlagen erkennbar sind, nicht spätestens bis zum Ablauf der in der Bekanntmachung benannten Frist zur Angebotsabgabe oder zur Bewerbung gegenüber dem Auftraggeber gerügt werden, </P><P>d. mehr als 15 Kalendertage nach Eingang der Mitteilung des Auftraggebers, einer Rüge nicht abhelfen zu wollen, vergangen sind. Satz 1 gilt nicht bei einem Antrag auf Feststellung der Unwirksamkeit des Vertrages nach § 101b Abs. 1 Nr. 2. §101a Abs. 1 Satz 2 bleibt unberührt.“</P></LODGING_OF_APPEALS_PRECISION></LODGING_OF_APPEALS></PROCEDURES_FOR_APPEAL><NOTICE_DISPATCH_DATE><DAY>18</DAY><MONTH>01</MONTH><YEAR>2018</YEAR></NOTICE_DISPATCH_DATE></COMPLEMENTARY_INFORMATION_CONTRACT_AWARD></FD_CONTRACT_AWARD></CONTRACT_AWARD></FORM_SECTION></TED_EXPORT>